Advertisement

Acta Neuropathologica

, Volume 39, Issue 2, pp 135–138 | Cite as

Clofibrate-induced myopathy in the rat

  • Heikki Teräväinen
  • Andreo Larsen
  • Matti Hillbom
Original Investigations

Summary

Rats were given daily injections of 0.2 or 0.5 g/kg chlorophenoxyisobutyrate (clofibrate) for 9 to 46 days. Lower leg muscles were studied with light and electron microscopy.

Daily treatment with 0.5 g/kg of the drug for 26–46 days caused myopathic changes.

Key words

Clofibrate Striated muscle Histochemistry Electron microscopy Experimental animal 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bridgeman, J. F., Rosen, A. M., Thorp, J. M.: Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia. LancetII, 502–506 (1972)Google Scholar
  2. Denizot, M., Farre, J., Pometta, D., Wildi, E.: Clofibrate, nephrotic syndrome and histological changes in muscle. LancetI, 1326 (1973)Google Scholar
  3. Green, K. G., Margetts, G.: Long-term follow-up of multicentre trial of ethyl-α-chlorophenoxyisobutyrate (clofibrate. “Atromid”-S) and clofibrate plus androsterone (“Atromid”). In: Progress in biochemical pharmacology, Vol. 2 (eds. D. Kritchevsky, R. Paoletti, D. Steinberg), pp. 378–392. Basel Karger 1967Google Scholar
  4. Guth, L., Samaha, F. J.: Procedure for the histochemical demonstration of actomyosin ATPase. Exp. Neurol.28, 365–367 (1977)Google Scholar
  5. Hess, R., Stäubli, W., Reiss, W., Reiss, W.: Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature208, 856–858 (1965)Google Scholar
  6. Katsilambros, N., Braaten, J., Ferguson, B. D., Bradley, R. F.: Muscular syndrome after clofibrate. N. Engl. J. Med.282, 1110 (1972)Google Scholar
  7. Langer, T., Levy, R. I.: Acute muscular syndrome associated with administration of clofibrate. N. Engl. J. Med.279, 856–858 (1968)Google Scholar
  8. Luft, J. H.: Improvements in Epoxy resin embedding methods. J. biophys. biochem. Cytol9, 409–414 (1961)Google Scholar
  9. Panini, S. R., Ramakrishna Kurup, C. K.: Mode of inhibition of mitochondrial energy transduction by chlorophenoxyisobutyrate. Biochem. J.142, 253–261 (1974)Google Scholar
  10. Pearse, A. G.: Oxidoreductases. In: Histochemistry, III ed. London: Churchill Livingstone 1972Google Scholar
  11. Pierides, A. M., Alvarez-Ude, F., Kerr, D. N. S., Skillein, A. W.: Clofibrate-induced muscle damage in patients with renal failure. LancetII, 1279 (1975)Google Scholar
  12. Reynolds, E. S.: The use of lead citrate at high pH as an electronopaque stain in electron microscopy. J. cell. Biol.17, 208–212 (1963)Google Scholar
  13. Sabatini, D. D., Bensch, K., Barrnett R. J.: Cytochemistry and electron microscopy. The preservation of cellular ultrastructure and enzymatic activity by aldehyde fixation. J. cell. Biol.17, 19–58 (1963)Google Scholar
  14. Smith, A. F., Macfie, W. G., Oliver, M. F.: Clofibrate, serum enzymes, and muscle pain. Brit. Med. J.2, 86–88 (1970)Google Scholar
  15. Teräväinen, H., Larsen, A.: Electrophysiological and structural studies on the effects of clofibrate on the peripheral nerves and motor end-plates. (To be published.)Google Scholar
  16. Watson, M. L.: Staining of tissue sections for electronmicroscopy with heavy metals. J. biophys. biochem. Cytol.4, 475–478 (1958)Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • Heikki Teräväinen
    • 1
  • Andreo Larsen
    • 1
  • Matti Hillbom
    • 1
  1. 1.Department of NeurologyUniversity of HelsinkiHelsinki 29Finland

Personalised recommendations